These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8131636)

  • 1. Carboplatin and etoposide as outpatient treatment of advanced non-small-cell lung cancer.
    Pronzato P; Landucci M; Vaira F; Vigani A; Bertelli G
    Chemotherapy; 1994; 40(2):144-8. PubMed ID: 8131636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.
    Johnson DH; DeVore R; Greco FA; Walls J; Thomas M; Hande KR; Hainsworth JD
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):50-6. PubMed ID: 1329223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study.
    Gridelli C; Rossi A; Scognamiglio F; Guida C; Fiore F; Gatani T; Scoppa G; Pergola M
    Anticancer Res; 1997; 17(6D):4755-8. PubMed ID: 9494602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
    Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
    Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
    Li DX; Chen XB
    Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged administration of oral etoposide alone or with intravenous carboplatin in stage IV non-small cell lung cancer: a randomized trial.
    Jeremic B; Shibamoto Y; Acimovic L; Milicic B; Milisavljevic S; Nikolic N
    Lung Cancer; 1997 Oct; 18(2):179-88. PubMed ID: 9316009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide/carboplatin/etoposide chemotherapy in patients with metastatic non-small cell lung cancer.
    Chang AY; Asbury RF; Boros L; Garrow GC; Hsieh S
    Semin Oncol; 1995 Jun; 22(3 Suppl 7):9-12. PubMed ID: 7610399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer.
    Ghielmini M; Pagani O; de Jong J; Pampallona S; Conti A; Maestroni G; Sessa C; Cavalli F
    Br J Cancer; 1999 Jun; 80(7):1058-61. PubMed ID: 10362116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer. Preliminary results of a Vanderbilt trial.
    Johnson DH; Hainsworth JD; DeVore R; Hande KR; Greco FA
    Oncology; 1992; 49 Suppl 1():57-61; discussion 61-2. PubMed ID: 1323813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-escalation study of oral etoposide and carboplatin in patients with advanced lung cancer.
    Atagi S; Furuse K; Kawahara M; Kodama N; Ogawara M; Kubota K; Matsui K; Kusunoki Y; Masuda N; Takada M; Negoro S; Fukuoka M
    Jpn J Clin Oncol; 1996 Oct; 26(5):316-21. PubMed ID: 8895671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Ozols RF
    J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.
    Yumuk PF; Turhal NS; Gumus M; Hatabay NF; Turken O; Ozkan A; Salepci T; Aliustaoglu M; Ahiskali R
    BMC Cancer; 2005 Jan; 5():10. PubMed ID: 15667664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged oral versus high-dose intravenous etoposide in combination with carboplatin for stage IV non-small-cell lung cancer (NSCLC): a randomized trial.
    Jeremic B; Shibamoto Y; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
    Lung Cancer; 1999 Sep; 25(3):207-14. PubMed ID: 10512132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of two platinum combinations in patients with advanced non-small cell lung cancer: a preliminary report. European Organization for the Research and Treatment of Cancer--Lung Cancer Working Party.
    Klastersky J; Sculier JP; Dabouis G; Bureau G; Libert P; Ravez P; Vandermoten G; Thiriaux J; Lecomte J; Cordier R
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):20-4. PubMed ID: 2154855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer.
    van Zandwijk N; ten Bokkel Huinink WW; Wanders J; Simonetti G; Dubbelman R; Franklin H; van Tinteren H; McVie JG
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):16-9. PubMed ID: 2154854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC).
    Weynants P; Humblet Y; Bosly A; Schallier D; Duprez P; Majois F; Beauduin M; Prignot J; Symann M
    Med Oncol Tumor Pharmacother; 1990; 7(4):219-22. PubMed ID: 2178205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin, methotrexate, and vinblastine in outpatients with advanced transitional cell carcinoma of the bladder.
    Pronzato P; Landucci M; Vaira F; Vigani A; Bertelli G
    Am J Clin Oncol; 1995 Jun; 18(3):223-5. PubMed ID: 7747710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide.
    Malacarne P; Santini A; Maestri A
    Oncology; 1996; 53(3):210-3. PubMed ID: 8643223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.